PANGROL 25,000 Hartkps.M.Magagenatzr. Pell., 100 pcs

Instructions for use for PANGROL 25,000 Hartkps.M.Magagenatzr. Pell., 100 pcs

Detailed instructions for PANGROL 25,000 Hartkps.M.Magagenatzr. Pell., 100 pcs

Field of use

• Medicines to replace digestive enzymes of the pancreas (the pancreatic enzymes).
• It is used for digestive disorders (maldigration) as a result of insufficient or missing function of the pancreas (exocrine pancreatic failure).

Active ingredients / ingredients / ingredients

266.2 mg pancreas powder (from pig)
25000 Pheur-E triacylglycerollipase
Amylase
Proteas
Cellulose, microcrystalline auxiliary material (+)
Chinoling elbing auxiliary substance (+)
Crooscarmellosis, sodium salt auxiliary material (+)
Iron (III) hydroxide oxide x-water Hedge substance (+)
Iron (III) oxid auxiliary material (+)
Eudragit L 30 D-55 Hedge substance (+)
Gelatine auxiliary substance (+)
Indigocarmin Hedge Terms (+)
Magnesium stair (Ph. EUR.) [pflanzlich] Hedge substance (+)
Castor oil, hydrogenated auxiliary material (+)
Silicium dioxide, high disperser auxiliary substance (+)
Simeticon emulsion 30% auxiliary material (+)
Talcum auxiliary material (+)
Titan dioxide HILDBOFT (+)
Triethyl citrat auxiliary substance (+)

Contradictions

• The medicine must not be taken:
  • with proven hypersensitivity to pork (pork energy) or another component.
  • during the strongly developed phase of disease of acute pancreatitis and in acute bumps of chronic pancreatitis.
• However, taking it can make sense if there is still a digestive disorder when an acute inflammatory push is subsided during the dietary construction phase.

dosage

• Take the medicine precisely after instruction from the doctor. Please ask your doctor or pharmacist if you are not quite sure.
• How much is to be taken?
  • Unless otherwise prescribed by the doctor, the usual dose per meal is a lipase content of EUR 13,000 - 26,000 pH. Units (corresponding to 1 to 2 capsules).
  • The dosage depends on the severity of the digestive weakness of the pancreas.
  • In patients with cystic fibrosis, the dose, taking into account the amount and composition of the meals, should not exceed the enzyme dose necessary for an appropriate fat recording.
  • The dose should only be increased under medical control and to improve symptoms. B. fat chair (steatorrhea) or abdominal pain.
  • A daily enzyme dose of EUR 15,000 - 20,000 pH. Units Lipase per kilogram of body weight should not be exceeded.
  • Please speak to your doctor or pharmacist if you have the impression that the effect of too strong or too weak is.

• Duration of the application
  • The duration of the application depends on the course of the disease and is determined by your doctor.

• If you have taken a larger amount than you should:
  • Even after taking larger quantities, symptoms of poisoning cannot be expected; Special treatment for overdose is therefore not required.
  • Overdosing pancreatin can lead to an increase in uric acid in blood and urine, particularly in the case of cystic fibrosis patients.
  • The recommended maximum dosage of EUR 15,000 - 20,000 pH. Units Lipase per kilogram of body weight per day should not be exceeded.

• If you have taken too little or forgot the intake:
  • If you have taken too little, the success of the treatment may fail in whole or in part, so that a digestive weakness can continue to be demonstrated.
  • Once you have forgotten you, please continue the therapy as recommended, without self -employedig to increase the following dose. If in doubt, ask your doctor or pharmacist.

• If you interrupt or cancel the intake
  • Please speak to your doctor if you want to end or interrupt the treatment independently.
  • If you interrupt the intake or end prematurely, you have to expect that the desired effect will not occur or that the clinical picture deteriorates.

• If you have any further questions about the application of the drug, ask your doctor or pharmacist.

Taking

• Take the capsules with plenty of liquid during the meal. If swallowing the capsules causes difficulties, they can be opened by careful things and at the same time rotating; Place the contained active ingredients in a spoon and - without chewing them! - swallow with a little liquid.

Patient information

• Particular caution when taking it is required:
  • in the case of intestinal narrowing (intestinal obstructions), which are known complications in patients with cystic fibrosis (congenital metabolic disorder). In the presence of intestinal obstruction-like signs, the possibility of intestinal narrowing should also be considered.
  • The preparation contains active enzymes that are released in the mouth, e.g. B. by chewing the gastric -resistant pellets contained in the capsules, oral mucosa damage can lead to damage. It is therefore important to ensure that the capsules or the pellets contained in the capsules are swallowed.

• Wateriness and operating machines:
  • By taking it, the reaction and perception as well as the judgment are not influenced, so that there is no effect on driving a motor vehicle or operating machines.

Pregnancy

no information available

Hints

Miscellaneous

It is important to be careful to swallow the preparation unz -chew, as it contains active enzymes that are released in the oral cavity, e.g. B. to be able to lead to mucosal damage (ulcerations of the oral mucosa). The blood sugar -lowering active ingredients (oral antidiabetics) acarbosis and miglitol can be reduced by taking the preparation at the same time. In individual cases, allergic reactions from the immediate type (such as rash, sneezing, tear flow, bronchospasm) and allergic reactions of the digestive tract are taken after taking pancreas Powder has been described. If this allergic reaction occurs, the preparation must be discontinued immediately and a doctor must be consulted immediately. In patients with a characteristic malfunction of the pancreas (cystic fibrosis), in individual cases, the formation of narrowing (strictures) is in individual cases. Darmages (ileozal region and colon ascenda) have been described. In the case of intestinal lock -like symptoms. Intestine is a known complication in patients with cystic fibrosis. If there is a symptoms -like symptoms, the possibility of intestinal narrowing should also be considered. In patients with cystic fibrosis, an increased uric acid excretion in urine can occur, especially with the intake of high doses of pancreatin. Therefore, uric acid excretion in these patients should be checked in the urine to avoid the formation of uric acid stonesten thrust of chronic pancreatitis during the florid phase of illness.